ClinicalTrials.gg

Program

alpha-tocotrienol quinone

Also written as “Vatiquinone”, “EPI-743” and “EPI-743 400 mg”.

Its studies are mostly in Friedreich Ataxia · Leigh Disease · Mitochondrial Diseases · Autistic Disorder · VLCAD deficiency, led by PTC Therapeutics.

Furthest: phase 3, since May 4, 202013 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PTC Therapeutics132 open or runningphase 3since May 4, 2020Nov 1, 2012Dec 31, 2027phase 3 · NCT05515536

Also a collaborator on its studies: axio-research-llc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 1, 2012First studies: 2 phase 2 studiesFirst studyNCT01721733, NCT01728064
  2. Mar 25, 2013Phase 2 study in Rett SyndromeNCT01822249 · 24 enrolled · Italy
  3. Apr 2, 2014Phase 2 study in VLCAD deficiencyNCT02104336 · 2 enrolled · United States
  4. Aug 11, 20143 phase 2 studiesNCT02257983, NCT02352896, NCT02226458
  5. May 4, 2020Phase 3 study in Mitochondrial DiseasesNCT04378075 · 68 enrolled · United States, Canada, France and more
  6. Sep 30, 2020Phase 3 study in Friedreich AtaxiaNCT04577352 · 146 enrolled · United States, Australia, Brazil and more
  7. Jan 19, 2022Phase 3 study in Leigh DiseaseNCT05218655 · 101 enrolled · United States, France, Italy and more
  8. Aug 1, 2022Phase 2 study in Friedreich AtaxiaNCT05485987 · 5 enrolled · United States
  9. Aug 23, 2022Phase 3 study in Friedreich AtaxiaNCT05515536 · 130 enrolled · United States, Australia, Brazil and more
  10. Jun 26, 2026Phase 3 study in Friedreich AtaxiaNCT07681713 · 120 planned · United States, Belgium, Brazil and more

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Friedreich AtaxiaNCT05515536
  2. Mar 15, 2029Primary completion: phase 3 study in Friedreich AtaxiaNCT07681713

TargetBeta

NQO1 →read by rule
“Quinone reductase 1 modulator”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07681713Friedreich Ataxia · United States, Belgium, Brazil and more3Not yet recruitingMar 15, 2029120
NCT05515536Friedreich Ataxia · United States, Australia, Brazil and more3Active, not recruitingDec 31, 2027130
NCT05485987Friedreich Ataxia · United States2CompletedAug 29, 20245
NCT05218655Leigh Disease · United States, France, Italy and more3CompletedApr 15, 2025101
NCT04577352Friedreich Ataxia · United States, Australia, Brazil and more3CompletedApr 4, 2023146
NCT04378075Mitochondrial Diseases · United States, Canada, France and more3TerminatedMar 18, 202368
NCT02352896Leigh Disease · United States2CompletedOct 30, 202330
NCT02226458Autism Spectrum Disorder2WithdrawnNov 30, 20150
NCT02257983Hearing Loss, Noise-Induced · United States2CompletedNov 30, 201577
NCT02104336VLCAD deficiency · United States2TerminatedNov 30, 20152
NCT01822249Rett Syndrome · Italy2CompletedDec 201324
NCT01728064Friedreich Ataxia · United States2CompletedOct 31, 201560
NCT01721733Leigh Disease · United States2CompletedFeb 28, 201535

How it is read

Names in the registry

  • “Vatiquinone”, 6 entries
  • “EPI-743”, 5 entries
  • “EPI-743 400 mg”, 1 entry
  • “EPI-743 200 mg”, 1 entry
  • “EPI-743 15 mg/kg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.